Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX-7101A in Adolescents with Uncomplicated Influenza
NCT06099873Phase 3Completed
- Sponsor
- Zenshine Pharmaceuticals Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing ZX-7101A with Placebo (2 arms). Primary endpoint: Time to the remission of all influenza symptoms at 15 days. Started Nov 2023; status: completed.
02
Drugs
Seloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06099873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099873.